Pitt Street Research 9July 2025

Pitt Street Research’s highlights (excerpts):

• “PTX-100 has shown strong potential in Phase 1, not just trouncing existing standards of care, but working in patients where previous treatments have failed.”
• How PTX-100 “with a price of US$450,000 (using Acrotech Biopharma’s Folotyn as a guide)...could make US$2.5bn in sales”
• “PTX-100 could be applicable to any cancer that could be defeated with an RAS therapy. This could be 22% of all cancers.”

https://static1.squarespace.com/static/5af533a312b13fb602fe7d7b/t/686cbe7b41a93627bbb447a9/1751957122744/Prescient%2BTherapeutics%2Bresearch%2Breinitiation%2Breport%2B09%2B07%2B2025.pdf%26sa=D%26source=docs%26ust=1753860831791383%26usg=AOvVaw3C2O3zkfeeFjSKzO_T_owX?utm_campaign=12916036-%5BLI%5D%20PTX%20MAY%202025&utm_medium=email&_hsenc=p2ANqtz-8FaeZexfGbynhz8idxrP5ZuTaNdcL9HNw7ud2mxrSPshmfJlkcMxwo-0CygJpjLsdQbzuKvITzyjmZUpzNhBeJtxH8pQ&_hsmi=11105965&utm_content=11105965&utm_source=hs_email